INTRODUCTION
============

Chronic inflammatory reactions induce metabolic diseases in various organs, resulting in cancer, obesity, diabetes, cardiovascular disease (CVD), neurodegeneration, and asthma ([@b1-pnfs-23-374]). Lipopolysaccharide (LPS) stimulates LPS-binding protein (LBP), toll-like receptor-4 (TLR4) ([@b2-pnfs-23-374],[@b3-pnfs-23-374]), and nuclear factor κB (NF-κB). NF-κB promotes production of pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6, tumor necrosis factor α (TNF-α), type 1 interferons (IFNs) such as IFN-β and IFN-γ and inflammation-related enzymes such as inducible nitric oxide (NO) synthase (iNOS), and cyclooxygenase-2 (COX-2) in the nucleus ([@b4-pnfs-23-374]--[@b6-pnfs-23-374]). NO has been reported to increase production of iNOS and reactive oxygen species (ROS), resulting in activation of inflammation ([@b7-pnfs-23-374]).

Naïve T cells are transformed into four different helper T (Th) cell types (Th1, 2, 17, and Treg) by various cytokines ([@b8-pnfs-23-374]). Each Th cell plays a different role depending on its type. Th1 regulates cellular immunity and intracellular pathogen clearance, Th2 regulates humoral immunity, extracellular pathogen clearance, and allergies, Th17 regulates tissue information and autoimmunity, and Treg regulates immune suppression ([@b8-pnfs-23-374]). Th1 and Th2 are well-known factors, and the balance between Th1 and Th2 is important ([@b9-pnfs-23-374]).

*Rumex crispus* (Rc) is a perennial plant belonging to the Polygonaceae family. The roots and leaves of Rc have been reported to have functional activities ([@b10-pnfs-23-374]). Rc is commonly consumed as a dried or processed herb or used as a medicinal product ([@b11-pnfs-23-374]), and is known to inhibit arachidonic acid induced inflammation in mice ([@b12-pnfs-23-374]). Rc also protects against liver injury ([@b12-pnfs-23-374]) and exhibits antioxidant ([@b13-pnfs-23-374]), anti-cancer ([@b14-pnfs-23-374]) and anti-obesity ([@b15-pnfs-23-374]) effects. Similarly, *Cordyceps militaris* (Cm) has been used since ancient times as an herbal ingredient ([@b16-pnfs-23-374]) and has been reported to have anti-inflammatory and anti-cancer effects ([@b11-pnfs-23-374],[@b17-pnfs-23-374]). Both Rc and Cm have been shown to have increased anti-inflammatory effects when mixed at various ratios. Specifically, Rc-Cm mixture (6:4), a product named AST2017-01, was shown to be the most effective in inducing synergistic anti-inflammatory effects in a human mast cell line (HMC-1) ([@b18-pnfs-23-374]). Jeong et al. ([@b18-pnfs-23-374]) reported that Rc-Cm reduced production of IL-1β, IL-6, and TNF-α in phorbol 12-myristate 13-acetate and calcium ionophore A23187 (PMACI)-treated HMC-1 cells.

Beopje is a processing method consisting of washing, steaming, dehydration, parching ([@b19-pnfs-23-374]), and processing of herbal ingredients for removal of anti-nutrients and enhancement of phytochemicals ([@b20-pnfs-23-374]). RC made using the Beopje method has been shown to have greater anti-inflammatory effects than that without Beopje in LPS-induced RAW 264.7 cells (data not shown) and mouse splenocytes ([@b21-pnfs-23-374]).

Taemyeongcheong (TMC) is a health functional beverage made using traditional methods in Korea, and is commonly found in various foods and herbal ingredients. TMC inhibits the allergic effects induced by 48/80 ([@b22-pnfs-23-374]) and acetaminophen-induced hepatic damage *in vivo* ([@b23-pnfs-23-374]). We have previously reported that TMC inhibited Th2 cytokines such as IL-1β, IL-6, and IL-10 as well as iNOS and COX-2 in LPS-induced RAW 264.7 cells ([@b24-pnfs-23-374]).

Therefore, we aimed to determine whether the natural product of Rc and Cs contributes to regulation of inflammation dependent on time and the presence of LPS in mice splenocytes. The healthy drink TMC, which contains a Rc-Cm mixture, was used as a positive control. In this study, we investigated the anti-inflammatory and immune cell regulatory responses of Rc-Cm and TMC treatment on pro-inflammatory cytokine protein levels (TNF-α, IFN-γ, IL-1β, and IL-6) and mRNA expression levels (IL-1β, IL-6, iNOS, and COX-2), as well as NO production in LPS-induced mice splenocytes.

MATERIALS AND METHODS
=====================

Sample preparation
------------------

Rc, Cm, and TMC were provided by Gawha Wellfood Co. (Jincheon, Chungbuk, Korea), and were freeze-dried. The Rc-Cm samples were mixed at a ratio of 6:4. TMC was made from the following ingredients: Rc (13.62%), Cm (11.14%), *Saururus chinensis* (11.14%), *Viscum album* (11.14%), *Houttuynia cordata* (11.14%), *Atractylodes ovata* (9.90%), *Capsella bursa-pastoris* (8.67%), *Cornus officinalis* (8.67%), *Phyllostachys bambusoides* leaf (7.43%), and *Cordyceps militaris* (7.15%). Processed Rc-Cm (Beopje) was prepared by washing, steaming, dehydrating, parching, and then dehydrating again. Rc-Cm was made by the same method as AST2017-01 ([@b18-pnfs-23-374]).

*Ex vivo* splenocytes collection and culture
--------------------------------------------

Mouse splenocytes were collected and cultured with slight modification to the methods described in Vitetta et al. ([@b25-pnfs-23-374]) and Amrouche et al. ([@b26-pnfs-23-374]). Ten 5-week-old C57BL/6 mice were purchased from Orient Bio (Seongnam, Gyeonggi, Korea) and used in the experiment. Mouse spleens were aseptically removed and immersed in Dulbecco Modified Eagle's Medium (DMEM, Sigma-Aldrich Co., St. Louis, MO, USA). To make single cell suspensions, spleens were chopped into small pieces using sterilized scissors. Cells were centrifuged at 1,500 rpm for 10 min to pellet, and resuspended to free cells. To quantify splenocyte proliferation, cells were counted using a hemocytometer and dispersed at a concentration of 2×10^6^ cells/mL in 6-well plates. Cells were cultured in DMEM containing 10% fetal bovine serum (Sigma-Aldrich Co.) and 100 units/mL of penicillin-streptomycin (PS, Welgene Inc., Gyeongbuk, Korea). Cells were cultured at 37°C with 5% CO~2~ ([@b20-pnfs-23-374]). This experiment was approved by the CHA University Animal Ethics Committee (IACUC-170149).

Quantitation of pro-inflammatory cytokines by enzymelinked immunosorbent assay (ELISA)
--------------------------------------------------------------------------------------

Splenocytes plated in 6-well plates were incubated for 24 h. After the medium was removed, 0.05 mg/mL of Rc-Cm and 0.1 mg/mL of TMC were added to each well. To induce inflammation, each well was treated with LPS (2 μg/mL, Sigma-Aldrich Co.). After incubation for 24, 48, and 72 h, the medium was collected. Concentrations of IL-6, IL-1β, IFN-γ, and TNF-α were measured in collected medium using an ELISA kit (BioLegend, San Diego, CA, USA). This experiment was performed according to the method provided by the manufacturer ([@b19-pnfs-23-374]).

mRNA quantitation of pro-inflammatory cytokines and inflammation-related genes in splenocytes by real time-quantitative polymerase chain reaction (RT-qPCR)
-----------------------------------------------------------------------------------------------------------------------------------------------------------

Splenocytes plated in 6-well plates were incubated for 24 h. After the medium was removed, 0.05 mg/mL of filtered (0.2 μm, GVS Filtration Inc., Bloomer, WI, USA) and freeze-dried Rc-Cm powder and 0.1 mg/mL of filtered (0.2 μm, GVS Filtration Inc.) and freeze-dried TMC powder were added to each well. To induce inflammation, each well was treated with LPS (2 μg/mL). After 48 h incubation, RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA, USA). The isolated RNA was quantified using a NanoDrop ND-1000 (NanoDrop Technologies Inc., Wilmington, DE, USA). Quantified RNA was reverse transcribed using Superscript II reverse transcriptase (Invitrogen) and synthesized into cDNA. The synthesized cDNA was amplified using a thermal cycler BioRad CFX-96 real time system (BioRad Laboratories, Hercules, CA, USA), and quantified. The primers used amplified 18s rRNA, IL-1β, IL-6, iNOS, and COX-2, and the primer sequences were as follows: 18s rRNA forward 5′-TCG AGG CCC TGT AAT TGG AA-3′ and reverse 5′-CCC TCC AAT GGA TCC TCG TT-3′, IL-1β forward 5′-AAG GGC TGC TTC CAA AC-3′ and reverse 5′-CTC CAC AGC CAC AAT GA-3′, IL-6 forward 5′-ATG AAG TTC CTC TCT GCA A-3′ and reverse 5′-AGT GGT ATC CTC TGT GAA G-3′, iNOS forward 5′-ATG GCT TGC CCC TGG AA-3′ and reverse 5′-TAT TGT TGG GCT GAG AA-3′, COX-2 forward 5′-GGC AGC AAA TCC TTG C-3′ and reverse 5′-TAT TGT TGG GCT GAG AA-3′ ([@b23-pnfs-23-374]).

NO production
-------------

NO production was measured by the nitrite concentration in the media using Griess reagent (Sigma-Aldrich Co.). Splenocytes plated in 6-well plates were incubated for 24 h. The medium was removed and exchanged for medium without FBS and PS for 24 h to induce starvation. After the medium was removed, 0.05 mg/mL of Rc-Cm and 0.1 mg/mL of TMC were added to each well. To induce inflammation, each well was treated with LPS (2 μg/mL). After 24, 48, and 72 h incubation, the medium was collected. The collected media were treated with Griess reagent, and the absorbance was measured at 550 nm using a Wallac Victor3 1420 Multilabel Counter (Perkin-Elmer, Wellesley, MA, USA) ([@b23-pnfs-23-374]).

Statistical analysis
--------------------

All data are presented as the mean±standard deviation (SD). Differences between the mean values for individual groups were assessed by one-way analysis of variance (ANOVA) of Duncan's multiple range test. Differences were considered significant when *P*\<0.05. The SPSS version 18 statistical software package (SPSS Inc., Westlands, Hong Kong) was used to perform analyses ([@b24-pnfs-23-374]).

RESULTS
=======

Levels of pro-inflammatory cytokines TNF-α, IFN-γ, IL-1β, and IL-6 in mice splenocytes
--------------------------------------------------------------------------------------

Treatment with Rc-Cm at a concentration of 0.005\~0.05 mg/mL did not significantly affect proliferation of RAW 264.7 cells after 24, 48, or 72 h of incubation (data not shown). In a previous study, TMC showed no cytotoxicity in RAW 264.7 cells at a concentration of 0.01\~0.1 mg/mL ([@b24-pnfs-23-374]).

### *TNF-*α *and IFN-*γ

LPS treatment significantly increased TNF-α, and IFN-γ levels compared to the control (*P*\<0.05) ([Fig. 1A and 1C](#f1-pnfs-23-374){ref-type="fig"}). LPS+TMC (91.7±23.9 pg/mL) treatment significantly reduced TNF-α protein levels compared to LPS (322.1±130.4 pg/mL) at 48 h (*P*\<0.05) ([Fig. 1A](#f1-pnfs-23-374){ref-type="fig"}). However, in the absence of LPS, Rc-Cm (334.8±37.0 pg/mL) and TMC (154.2±48.4 pg/mL) treatments significantly increased TNF-α protein levels compared to the control (2.0±2.5 pg/mL) at 48 h (*P*\<0.05) ([Fig. 1B](#f1-pnfs-23-374){ref-type="fig"}). LPS+Rc-Cm (49.5±11.5 pg/mL) and LPS+TMC (54.7±2.4 pg/mL) treatments significantly reduced IFN-γ protein levels compared to LPS (76.5±20.8 pg/mL) at 48 h (*P*\<0.05) ([Fig. 1C](#f1-pnfs-23-374){ref-type="fig"}). However, Rc-Cm (66.6±8.7 pg/mL) treatment significantly increased IFN-γ protein levels compared to the control (42.5±10.3) at 48 h (*P*\<0.05) ([Fig. 1D](#f1-pnfs-23-374){ref-type="fig"}). Moreover, LPS+Rc-Cm treatment resulted in a similar TNF-α level compared to LPS treatment at 48 h.

### *IL-1*β *and IL-6*

LPS significantly increased IL-1β and IL-6 levels compared to the control (*P*\<0.05) ([Fig. 1E and 1G](#f1-pnfs-23-374){ref-type="fig"}). LPS+Rc-Cm (113.8±13.8 pg/mL) and LPS+TMC (145.9±11.5 pg/mL) treatments significantly reduced IL-1β protein levels compared to LPS (260.9±42.3 pg/mL) at 48 h (*P*\<0.05) ([Fig. 1E](#f1-pnfs-23-374){ref-type="fig"}), whereas TMC (287.5±97.2 pg/mL) treatment significantly increased IL-1β protein levels compared to the control (165.1±27.1 pg/mL) at 48 h ([Fig. 1F](#f1-pnfs-23-374){ref-type="fig"}). LPS+Rc-Cm (476.8±214.7 pg/mL) and LPS+TMC (720.9±159.8 pg/mL) treatments significantly reduced IL-6 protein levels compared to LPS (1,291.1±339.3 pg/mL) at 48 h (*P*\<0.05) ([Fig. 1G](#f1-pnfs-23-374){ref-type="fig"}), whereas Rc-Cm (446.2±209.4 pg/mL) and TMC (550.4±57.6 pg/mL) treatments significantly increased IL-6 protein levels compared to the control (54.2±21.3 pg/mL) at 48 h (*P*\<0.05) ([Fig. 1H](#f1-pnfs-23-374){ref-type="fig"}). Thus, Rc-Cm and TMC reduced production of pro-inflammatory cytokines in LPS-induced splenocytes but increased pro-inflammatory cytokine production in naïve splenocytes.

mRNA expression levels of pro-inflammatory cytokines IL-1β and IL-6 in mice splenocytes
---------------------------------------------------------------------------------------

Previously, we reported that TMC inhibited Th2 cytokines in RAW 264.7 cells ([@b21-pnfs-23-374]). Therefore, in this study, we investigated whether Rc-Cm and TMC interfere with mRNA expression of the Th2 cytokines IL-1β and IL-6 in splenocytes. The mRNA expression levels of IL-1β and IL-6 are shown in [Fig. 2](#f2-pnfs-23-374){ref-type="fig"}. Rc-Cm and TMC significantly increased IL-1β and IL-6 levels compared to the control, which is similar to the results shown in [Fig. 1](#f1-pnfs-23-374){ref-type="fig"}. LPS increased mRNA levels of these cytokines in splenocytes compared to the control (*P*\<0.05). In addition, LPS+Rc-Cm and LPS+TMC significantly reduced expression levels of IL-1β (0.27 and 0.08) and IL-6 (0.12 and 0.13) compared to LPS (1.00) (*P*\<0.05). However, expression levels of pro-inflammatory cytokines were significantly elevated in the absence of LPS ([Fig. 2](#f2-pnfs-23-374){ref-type="fig"}).

mRNA expression of inflammation-related genes in mice splenocytes
-----------------------------------------------------------------

mRNA expression levels of iNOS and COX-2 are shown in [Fig. 3](#f3-pnfs-23-374){ref-type="fig"}. Rc-Cm and TMC treatments did not significantly affect iNOS and COX-2 expression compared to the control. LPS-induced mice splenocytes showed significantly increased mRNA levels compared to the control. LPS+Rc-Cm and LPS+TMC treatments significantly reduced iNOS (0.39 and 0.08) and COX-2 (0.52 and 0.14) levels compared to LPS (1.00) (*P*\<0.05). Thus, Rc-Cm and TMC reduced inflammation-related genes in LPS-induced splenocytes but not in naïve splenocytes.

NO production in mice splenocytes
---------------------------------

LPS-treated splenocytes showed significant time-dependent elevation of NO production compared to the control ([Fig. 4](#f4-pnfs-23-374){ref-type="fig"}). Splenocytes treated with LPS+Rc-Cm (1.59±0.31 μM) and LPS+TMC (1.04±0.33 μM) showed significantly lower NO levels than LPS-treated splenocytes (2.39±0.51 μM) at 48 h (*P*\<0.05). Rc-Cm (1.06±0.07 μM) and TMC (0.79±0.34 μM) treatments did not significantly affect NO levels compared to the control (0.93±0.08 μM) at 48 h.

DISCUSSION
==========

LPS stimulates mammalian cells to interact with multiple proteins such as LBP and TLR4 ([@b2-pnfs-23-374],[@b3-pnfs-23-374]). TLR4 activated by LPS induces NF-κB, and activated NF-κB promotes transcription of the pro-inflammatory cytokines IL-1β, IL-6, TNF-α, type 1 IFNs, iNOS, and COX-2 in the nucleus ([@b4-pnfs-23-374]--[@b6-pnfs-23-374]). NO is recognized as one of the most multifunctional players in the immune system and is derived from the amino acid L-arginine via the enzymatic activity of iNOS ([@b27-pnfs-23-374]). Patients with cancer, obesity, and type 2 diabetes exhibit increased circulating levels of IL-1, IL-6, and TNF-α ([@b28-pnfs-23-374],[@b29-pnfs-23-374]), and NO is involved in tumor formation, chronic degenerative disease, autoimmune processes, and control of infectious diseases ([@b27-pnfs-23-374]). Upon initiation of inflammation, an immune response is triggered, and a variety of immune cells are activated. Th cells are important in the immune response and produce various cytokines ([@b30-pnfs-23-374]). Th can be classified based on the type of cytokine they produce. Th1 produce TNF-α, IFN-γ, and IL-12, whereas Th2 produce IL-4, IL-5, IL-6, and IL-10 ([@b30-pnfs-23-374]). IL-1β stimulates Th2 and promotes cytokine production by Th2 ([@b31-pnfs-23-374]).

Rc-Cm inhibited the pro-inflammatory cytokines TNF-α and IFN-γ for Th1 and IL-1β and IL-6 for Th2. These results indicate that Rc-Cm suppresses pro-inflammatory cytokines activated by LPS and reduced inflammation. It was previously reported that TMC reduces production of Th2 cytokines (IL-1β, IL-6, and IL-10) ([@b24-pnfs-23-374]). Thus, a health beverage containing Rc-Cm (TMC) may inhibit both Th1 and Th2 inflammatory activities through suppression of pro-inflammatory cytokines.

Rc has previously been shown to inhibit inflammation in arachidonic acid and carrageenan-induced mice ([@b12-pnfs-23-374]). Cm has been shown to inhibit iNOS and COX-2 in rats ([@b32-pnfs-23-374]) and as iNOS and COX-2 in LPS-induced RAW 264.7 cells ([@b33-pnfs-23-374]). In this study, Rc-Cm and TMC suppressed iNOS and COX-2 mRNA expression and NO production in LPS-induced splenocytes. Rc-Cm demonstrated better anti-inflammatory effects than TMC ([Fig. 2](#f2-pnfs-23-374){ref-type="fig"} and [3](#f3-pnfs-23-374){ref-type="fig"}) due to differences between the ingredient mixture and healthy drink. These results indicate that Rc-Cm reduced production of both of Th1 and Th2 cytokines and decreased expression of the inflammation-related genes iNOS and COX-2 in LPS-induced mice splenocytes. Rc-Cm in TMC are likely to be the major ingredients with anti-inflammatory effects.

Rc with processing (120 μg/g) showed increased production of the active compound chrysophanol compared to Rc without Beopje (70.8 μg/g) (data not shown). Cm contains cordycepin, which has been shown to suppress phytohemagglutinin-induced inflammation in peripheral blood mononuclear cells ([@b34-pnfs-23-374]). Joeng et al. ([@b18-pnfs-23-374]) reported that a 6:4 ratio of Rc-Cm and chrysophanol had anti-inflammatory effects in PMACI-treated HMC-1 cells. Thus, a 6:4 ratio had synergistic anti-inflammatory effects since chrysophanol and cordycepin regulate inflammation. Based on these results, a 6:4 ratio and phytochemicals of chrysophanol and cordycepin in Rc-Cm are optimal for development of immunoregulatory (atopic dermatitis, asthma, and allergy) products.

Rc has been shown to reduce NO production in LPS-induced RAW 264.7 cells ([@b35-pnfs-23-374]), and Cm has been shown to reduce NO production in rat brain microvascular endothelial cells injured by oxygen-glucose deprivation ([@b36-pnfs-23-374]). In a previous study, TMC reduced NO production in RAW 264.7 cells ([@b21-pnfs-23-374]). In this study, Rc-Cm decreased NO production in LPS-induced splenocytes at 48 and 72 h. Therefore, Rc-Cm suppressed pro-inflammatory cytokines, iNOS, COX-2, and NO production activated by LPS. Thus, Rc-Cm decreased inflammatory stimuli in toxic agent (i.e., LPS)-induced immune cells.

Rc-Cm and TMC increased cytokine levels in mouse splenocytes but had no effect on production of iNOS, COX-2, and NO in the absence of LPS. Compound A induced Th2 cell activity in splenocytes in the absence of LPS ([@b37-pnfs-23-374]). In addition, naringenin activated Th cells in splenocytes in the absence of LPS ([@b38-pnfs-23-374]). Therefore, Rc-Cm stimulated pro-inflammatory cytokine production in splenocytes in the absence of LPS. Taken together, Rc-Cm inhibited toxic agent (i.e., LPS)-induced inflammation but promoted immune cell activities. Elevation of immune cell activities did not affect inflammation since levels of iNOS, COX-2, and NO production were not increased in mouse splenocytes in the absence of LPS. Therefore, Rc-Cm can regulate inflammation and immune cell responses.

In conclusion, Rc-Cm decreased production of the LPS-induced pro-inflammatory cytokines TNF-α, IFN-γ, IL-1β, and IL-6 and inhibited expression of LPS-induced inflammation-related enzymes iNOS and COX-2, and NO production. However, Rc-Cm regulated immune cell (Th1 and Th2) responses were not associated with elevation of inflammation-related factors in mouse splenocytes in the absence of LPS. These results indicate that Rc-Cm is rich in health beneficial phytochemicals (chrysophanol and cordycepin), and that these phytochemicals regulate LPS-induced inflammation and immune cell responses. Therefore, consumption of the natural anti-inflammation ingredients Rc and Cm could be effective for treatment of atopic dermatitis, asthma, and allergies, and they could be used to make various products (drugs, beverages, etc.).
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